Wisconsin is currently home to 1261 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
NCT05622318
Recruiting
This is an open-label phase 2 study designed to explore the efficacy and safety of low-dose PTCy-ruxolitinib GVHD prophylaxis in older adults undergoing allogeneic HCT with a matched sibling or unrelated donor with a peripheral blood stem cell graft.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
09/27/2024
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Graft-versus-host Disease
Register for Updates
Preemptive Ibuprofen Effects on Pain Perception Following Extraction and Bone Graft
NCT05919745
Recruiting
The goal of this randomized clinical trial is to compare patient-reported pain and oral health-related quality of life during the first postoperative week following extraction and bone graft surgery in patients who received preemptive ibuprofen versus placebo. Participants will receive ibuprofen 600mg or placebo by mouth with water 1 hour prior to extraction and bone graft surgery. The primary question it aims to answer is: • Does preemptive ibuprofen have an effect on postoperative pain 1 hou... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2024
Locations: Marquette University School of Dentistry Graduate Periodontics Clinic, Milwaukee, Wisconsin
Conditions: Pain, Post Operative, Quality of Life
Register for Updates
Immunogenicity of HPV Vaccine in Transplant Recipients.
NCT05557370
Recruiting
To measure levels of HPV antibodies in post-solid-organ transplant recipients who have gotten the HPV9 vaccine.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
09/25/2024
Locations: Froedtert Lutheran Memorial Hospital, Milwaukee, Wisconsin
Conditions: Chronic Kidney Diseases, Kidney Transplant
Register for Updates
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
NCT03827694
Recruiting
This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).
Gender:
ALL
Ages:
Between 120 days and 21 years
Trial Updated:
09/24/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pulmonary Invasive Aspergillosis, Pulmonary Invasive Fungal Infections
Register for Updates
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
NCT06031428
Recruiting
The study is a randomized control trial involving 100 participants (formerly incarcerated Black men with poorly controlled diabetes) to examine the effect of a tailored nurse case manager on glycemic control and other clinical outcomes, self-care behaviors, and quality of life at 6 months post-randomization.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/20/2024
Locations: Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Screening Emotions in Adolescents at the Hospital for mTBI
NCT06370520
Recruiting
The goal of this observational study is to develop and validate a clinical tool to predict which adolescents aged 11 to less than 18 years of age with mild traumatic brain injury (mTBI) are at an increased risk for developing significant new or worsening mental health conditions. The main aims the study wish to answer are: * Does the adolescent have new or worsening depression or anxiety defined as a change from their previous medical history using self-reported questionnaires at either one or... Read More
Gender:
ALL
Ages:
Between 11 years and 17 years
Trial Updated:
09/19/2024
Locations: The Medical College of Wisconsin, Inc., Milwaukee, Wisconsin
Conditions: Brain Injury Traumatic Mild, Brain Injuries, Brain Injuries, Acute, Head Injury With Intracranial Hemorrhage, Head Injury Trauma, Brain Injury Traumatic Focal With Loss of Consciousness, Skull Fractures, Diffuse Axonal Injury, Intracranial Hemorrhages, Head Injury
Register for Updates
Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)
NCT06305715
Recruiting
This prospective, two-part, single-arm, phase II trial is designed to evaluate whether the use of definitive radiation to the primary lung lesion prolongs progression-free survival (PFS) in treatment-naïve, metastatic, driver-mutated non-small cell lung cancers (NSCLC) patients who are subsequently placed on a tyrosine kinase inhibitor (TKI).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2024
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Non Small Cell Lung Cancer
Register for Updates
Dementia Care Partner Hospital Assessment Tool
NCT05592366
Recruiting
The purpose of this study is to see whether an adapted questionnaire called the Care Partner Hospital Assessment Tool (CHAT) for care partners of hospitalized patients living with Alzheimer's disease and related dementias (ADRD) (CHAT-AD) can help people with dementia receive better care after they go home from the hospital. Participants will be a care partner ('family member or friend') who provides unpaid care to a hospitalized adult relative or partner to help them take care of themselves bec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Alzheimer Disease, Dementia
Register for Updates
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Neuroblastoma
Register for Updates
Randomized Evaluation of Machine Learning Assisted Radiation Treatment Planning Vs Standard Radiation Treatment Planning
NCT05979883
Recruiting
The purpose of this study is to determine the magnitude of clinical benefit achieved through machine learning assisted radiation treatment planning (MLAP) on post-treatment clinical outcomes such as acute toxicity and patient reported outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin
Conditions: Cancer Head Neck, Cancer, Head, Cancer Neck
Register for Updates
Study of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019
Recruiting
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
Register for Updates
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
NCT04038502
Recruiting
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. P... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin
Conditions: Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
Register for Updates